欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2007, Vol. 12 ›› Issue (5): 591-596.

• 临床药理学 • 上一篇    下一篇

在中国汉族健康女性志愿者上进行的两种复方孕二烯酮片生物等效性研究

方翼1, 柴栋1, 王锡萍1, 郑专杰1, 曹霖2, 朱忠义2, 王睿1   

  1. 1中国人民解放军总医院临床药理研究室,北京 100853;
    2上海市计划生育科学研究所,上海 200032
  • 收稿日期:2007-03-02 修回日期:2007-04-19 发布日期:2020-10-29
  • 通讯作者: 王睿,女,教授,博士生导师,主要从事临床药理学研究。Tel:010-66939409 E-mail:wangrui301@vip.sina.com
  • 作者简介:方翼,男,副主任药师,主要从事临床药理学研究。Tel:010-66937908 E-mail:fyGK7000@163.com

Pharmacokinetic and bioequivalence studies of compound gestodene tablet in Chinese healthy female adult volunteers

FANG Yi1, CHAI Dong1, WANG Xi-ping1, ZHENG Zhuan-jie1, CAO Lin2, ZHU Zhong-yi2, WANG Rui1   

  1. 1Institute of Clinical Pharmacology, Chinese PLA General Hospital, Beijing 100853, China;
    2Shanghai Institute of Planned Parenthood Research, Shanghai 200032, China
  • Received:2007-03-02 Revised:2007-04-19 Published:2020-10-29

摘要: 目的: 研究国产(试验制剂)和进口(参比制剂)两种复方孕二烯酮片在中国健康成年女性志愿者体内的药代动力学行为,评估两者的生物等效性,建立人体血清中孕二烯酮和炔雌醇浓度测定的放射免疫分析方法(RIA)。方法: 24名健康成年女性志愿者按两周期双交叉自身对照实验设计,分别单次口服试验制剂和参比制剂1 片。于给药后0.25、0.5、0.75、1、1.5、2、4、6、8、12、24、36、48、72 h 取上肢静脉血7 mL,应用RIA 法测定各受试者给药后不同时间点的血药浓度。应用DAS 统计软件进行数据处理,求算其药动学参数,考察其生物等效性。结果: 试验制剂和参比制剂的主要药代动力学参数:试验制剂和参比制剂中孕二烯酮的t max 分别为(1.00 ±0.00)、(1.01 ±0.12)h ;Cmax 分别为(2756 ±287)、(2571 ±387)ng/L;AUC0 -t 分别为(23400 ±4288)、(26275 ±4609)ng·L-1/h ;t 1 2 分别为( 13 .1 ±1 .6) 、(14 .5 ±2 .2) h ;试验制剂和参比制剂中炔雌醇的tmax分别为( 1 .54 ±0 .25) 、( 1 .75 ±0 .25) h ;Cmax 分别为( 138 ±13) 、( 142 ±16) ng/L ;AUC0 -t分别为( 2311±558) 、( 2266 ±637) ng/L-1/h ; 1 2β分别为( 28 ±7) 、(31 ±8) h 。试验制剂中孕二烯酮和炔雌醇的相对生物利用度分别为88 .97 %、102 .87 %。结论: 建立的分析方法准确灵敏, 两种制剂所含的两种成分均生物等效。

关键词: 复方孕二烯酮片, 孕二烯酮, 炔雌醇, 放射免疫分析方法, 药代动力学, 生物等效性

Abstract: AIM: To establish RIA method for determination of gestodene and aethinyloestradiol in blood serum, and investigate the pharmacokinetics and bioequivalence of compound gestodene tablet in Chinese healthy female adult volunteers. METHODS: Twenty-four female healthy volunteers were randomized to eceive a single crossover oral dose of compound gestodene reference tablet or domestic tablet. Seven mL venous blood was taken at time 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48, 72 h after administration. The concentrations of gestodene and aethinyloestradiol in blood serum were determined by RIA. The data were managed by DAS Software. RESULTS: The main pharmacokinetic parameters of test and reference compound gestodene tablets were as following :tmax of gestodene were (1.00 ±0.00) and (1.01 ±0.12)h ;their Cmax were (2756±287) and (2571±387) ng/L ;AUC0 -t were (23400 ±4288) and (26275±4609)ng/L-1/h ;t1 2 were (13.1 ±1.6) and (14.5 ±2.2) h ;tmax of aethinyloestradiol were (1.54 ±0.25) and (1.75±0.25) h ;Cmax were (138 ±13) and (142 ±16) ng/L;AUC0-t :were (2311±558 ) and (2266±637 )ng/L-1/h ;t1 2βwere (28 ±7) and (31 ±8) h. The relative bioavailabilities of gestodene and aethinyloestradiol of test tablet were 88.97 % and 102.87 %. CONCLUSION: The assay method is shown to be sensitive and accurate giving reliable results. The test tablet was bioequivalent to the reference tablet.

Key words: compound gestodene tablet, gestodene, aethinyloestradiol, radioimmupoassay, pharmacokinetics, bioequivalence

中图分类号: